Nor did we find a significant difference in platelet aggregation response in HHT-patients compared with the control group for all agonists (thrombin receptor activating peptide, adenosine diphosphate and collagen-related peptide). The gene discussed is F2R; the disease is hereditary hemorrhagic telangiectasia.